10/510,626

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	444	(514/254.01).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:03
L2	3	l1 and alpha-4 adj integrin	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:15
L3	2525	(514/326).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:15
L4	5	l3 and alpha-4 adj integrin	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:25
L5	2204	(514/423).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:26
L6	5	l5 and alpha-4 adj integrin	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:30
L7	755	(548/537).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:30
L8	1	l7 and alpha-4 adj integrin	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:31
L9	1517	(546/208).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:31
L10	5	l9 and alpha-4 adj integrin	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:32
L11	926	(544/372).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:33
L12	3	l11 and alpha-4 adj integrin	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/26 16:33

50613257

10/510,626

ADD'L STN SEARCH

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 4	DEC 18	CA/CAplus patent kind codes updated
NEWS 5	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 7	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 13	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 14	JAN 29	PHAR reloaded with new search and display fields
NEWS 15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19	FEB 26	MEDLINE reloaded with enhancements
NEWS 20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25	MAR 16	CASREACT coverage extended
NEWS 26	MAR 20	MARPAT now updated daily
NEWS 27	MAR 22	LWPI reloaded

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

Erich Leeser

50613257

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:25:14 ON 26 MAR 2007

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:25:30 ON 26 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAR 2007 HIGHEST RN 928121-90-8
DICTIONARY FILE UPDATES: 25 MAR 2007 HIGHEST RN 928121-90-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\carmella.str

Erich Leeser

50613257





chain nodes :
6 7 8 9 10 11 12 13 15 17 18 19 20 24 27 28
ring nodes :
1 2 3 4 5
chain bonds :
1-27 5-6 6-7 6-20 7-8 7-24 8-9 8-10 10-11 10-17 10-18 11-12 12-13
12-19 13-28 15-28
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-27 6-7 6-20 7-8 7-24 10-11 11-12 12-13 12-19 13-28 15-28
exact bonds :
2-3 3-4 4-5 5-6 8-9 8-10 10-17 10-18
isolated ring systems :
containing 1 :

G1:C,O,S,N,Cy

G2:C,O,N

G3:O,S

G4:C,H

G5:C,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom 15:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 24:CLASS 27:CLASS 28:CLASS

Erich Leeser

50613257

L1 STRUCTURE UPLOADED

=> S L1
SAMPLE SEARCH INITIATED 13:25:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 21708 TO ITERATE

9.2% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 425341 TO 442979
PROJECTED ANSWERS: 20 TO 414

L2 1 SEA SSS SAM L1

=> S L1 FULL
FULL SEARCH INITIATED 13:26:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 432834 TO ITERATE

99.2% PROCESSED 429264 ITERATIONS 134 ANSWERS

100.0% PROCESSED 432834 ITERATIONS 134 ANSWERS
SEARCH TIME: 00.00.18

L3 134 SEA SSS FUL L1

=> FILE CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	172.76

FILE 'CAPLUS' ENTERED AT 13:26:36 ON 26 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Mar 2007 VOL 146 ISS 14
FILE LAST UPDATED: 25 Mar 2007 (20070325/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L3

Erich Leeser

50613257

L4 7 L3

=> S L3 FULL
L5 7 L3

=> S L5 AND PY<2003
22870145 PY<2003
L6 5 L5 AND PY<2003

=> D IBIB ABS HITSTR

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:137020 CAPLUS
DOCUMENT NUMBER: 134:193741
TITLE: Preparation of peptide derivatives as cell adhesion inhibitors
INVENTOR(S): Lee, Wen-Cherng; Scott, Daniel; Cornebise, Mark; Petter, Russell
PATENT ASSIGNEE(S): Biogen, Inc., USA
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001012186	A1	20010222	WO 2000-US22285	20000814	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2380817	A1	20010222	CA 2000-2380817	20000814	<--
BR 2000013248	A	20020723	BR 2000-13248	20000814	<--
HU 200202469	A2	20021128	HU 2002-2469	20000814	<--
EP 1265606	A1	20021218	EP 2000-959232	20000814	<--
EP 1265606	B1	20061025			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
JP 2003506491	T	20030218	JP 2001-516532	20000814	
EE 200200070	A	20030415	EE 2002-70	20000814	
US 6630503	B1	20031007	US 2000-638652	20000814	
NZ 517011	A	20040227	NZ 2000-517011	20000814	
AU 780610	B2	20050407	AU 2000-70586	20000814	
AT 343383	T	20061115	AT 2000-959232	20000814	
EP 1741428	A2	20070110	EP 2006-21333	20000814	
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
IN 2002DN00160	A	20061229	IN 2002-DN160	20020207	
ZA 2002001158	A	20030512	ZA 2002-1158	20020211	
NO 2002000725	A	20020408	NO 2002-725	20020213	<--
BG 106510	A	20021031	BG 2002-106510	20020311	<--
HK 1051500	A1	20070202	HK 2003-103786	20030527	
US 2004132809	A1	20040708	US 2003-677756	20031003	

Erich Leeser

50613257

US 7034043	B2	20060425			
US 2006166961	A1	20060727	US 2006-362043		20060227
PRIORITY APPLN. INFO.:			US 1999-148845P	P	19990813
			EP 2000-959232	A3	20000814
			US 2000-638652	A1	20000814
			WO 2000-US22285	W	20000814
			US 2003-677756	A1	20031003

OTHER SOURCE(S): MARPAT 134:193741

AB Cell adhesion inhibitors of the general formula R3-L-L'-R1 (R1 = H, C1-10alkyl, C2-10alkenyl or -alkynyl, cycloalkyl, cycloalkylalkyl, -alkenyl, or -alkynyl; L' and L are hydrocarbon linker moieties having 1-5 or 1-14 carbons, resp., which are optionally substituted and interrupted by, or terminally attached to, various groups; R3 = alkyl, cycloalkyl, aryl, aralkyl, aryloxy, arylamino, heterocyclyl, etc.) were prepared An inhibitor of the present invention interacts with VLA-4 mols. to inhibit VLA-4 dependent cell adhesion. Thus, N2-[N-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl]-N4-[N-(o-MePUPA)-N-methyl-L-leucyl]-L-2,4-diaminobutyric acid [o-MePUPA = [4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl] was prepared via peptide coupling reactions in solution

IT 327612-34-0P 327612-36-2P 327612-43-1P
327612-45-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide derivs. as cell adhesion inhibitors)

RN 327612-34-0 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



Erich Leeser



RN 327612-36-2 CAPLUS
CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[[[(2S)-1-[(4,5,6,7-tetrahydro-4-oxo-3-benzofuranyl)carbonyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327612-43-1 CAPLUS
CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[[[(2S)-1-(difluorophenylacetyl)-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

50613257



RN 327612-45-3 CAPLUS
CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[[[(2S)-1-(difluorophenylacetyl)-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D IBIB ABS HITSTR 2-5

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:144899 CAPLUS
DOCUMENT NUMBER: 132:189658
TITLE: Amino acid derivative and peptide anti-cancer compounds and methods
INVENTOR(S): Stewart, John M.; Chan, Daniel C. F.; Gera, Lojos; York, Eunice; Bunn, Paul
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

Erich Leeser

50613257

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2000011022	A1	20000302	WO 1999-US19381		19990820	<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
US 6388054	B1	20020514	US 1999-378019		19990819	<--
AU 2000015959	A1	20000314	AU 2000-15959		19990820	<--
PRIORITY APPLN. INFO.:			US 1998-97210P	P	19980820	
			US 1999-141169P	P	19990625	
			US 1999-378019	A	19990819	
			WO 1999-US19381	W	19990820	

OTHER SOURCE(S): MARPAT 132:189658

AB The invention provides amino acid derivative and peptidic compds. useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula [ACA]n-X [X = linker group with 2-5 functional groups or is absent; n = 1; ACA as described in the invention (Markush included)].

IT 259882-66-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide and non-peptide anti-cancer compds. and methods)

RN 259882-66-1 CAPLUS

CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-3-[[D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl]amino]-L-alanyl-(2S)-2-(2,3-dihydro-1H-inden-2-yl)glycyl-L-seryl-(2R)-2-(2,3-dihydro-1H-inden-2-yl)glycyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Erich Leeser

50613257

PAGE 1-A



* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

PAGE 3-A



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:68848 CAPLUS

Erich Leeser

50613257

DOCUMENT NUMBER: 120:68848
TITLE: 3D-QSAR three-dimensional quantitative structure-activity relationship of angiotensin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and complementary-receptor-field alignment rules
AUTHOR(S): Waller, Chris L.; Marshall, Garland R.
CORPORATE SOURCE: Cent. Mol. Des., Washington Univ., St. Louis, MO, 63130-4899, USA
SOURCE: Journal of Medicinal Chemistry (1993), 36(16), 2390-403
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The utility of comparative mol. field anal. (CoMFA), a three-dimensional Quant. Structure-Activity Relationship (3-D QSAR) paradigm, as a tool to aid in the development of predictive models has been previously addressed (Depriest, S. D. et al., J. Am. Chemical Society 1993, in press). Although predictive correlations were obtained for angiotensins-converting and thermolysin inhibitors, certain inadequacies of the CoMFA technique were noted. Primarily, CoMFA steric and electrostatic fields alone do not fully characterize the zinc-ligand interaction. Previously, this was partially rectified by the inclusion of indicator variables into the QSAR table to designate the class of zinc-binding ligand. Recent advances in mol. modeling technol. have allowed us to further address this limitation of the preceding study. Using MO fields derived from semiempirical calcns. as addnl. descriptors in the QSAR table, predictive correlations were produced based on CoMFA and MO fields alone-indicator variables no longer being necessary. Arbitrary information concerning the alignment of mols. under study within the active-site introduces ambiguities into the CoMFA study. Crystallog. information detailing the binding mode of several thermolysin enzyme inhibitors has previously been used as a guide for the alignment of addnl., noncrystd., inhibitors. However, this process was complicated by the lack of parameters for zinc in the mol. mech. force field. Therefore, zinc-ligand interactions were ignored during the standard minimization procedure. The use of field-fit minimization using complementary receptor fields as templates is presented as a possible solution to the problem. Predictive correlations were obtained from analyses based on this method of mol. alignment. The availability of crystallog. data for thermolysin enzyme-inhibitor complexes allowed for an alternate definition of the CoMFA region. Herein, promising results from analyses using actual receptor active-site atom probe atoms are presented.
IT 127413-69-8 127413-75-6
RL: BIOL (Biological study)
(angiotensin-converting enzyme inhibition by, QSAR of)
RN 127413-69-8 CAPLUS
CN L-Proline, 1-[N-[1-[(phenylmethoxy)carbonyl]-L-prolyl]-D-γ-glutamyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Erich Leeser

50613257



RN 127413-75-6 CAPLUS
CN D-Norvaline, 5-(2-carboxyoctahydro-1H-indol-1-yl)-5-oxo-N-[1-[(phenylmethoxy)carbonyl]-L-prolyl]-, [2S-(2α,3aβ,7aβ)]-(9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:406781 CAPLUS
DOCUMENT NUMBER: 113:6781
TITLE: Angiotensin-converting enzyme inhibitors: synthesis and structure-activity relationships of potent N-benzyloxycarbonyl tripeptide inhibitors
AUTHOR(S): Sawayama, Tadahiro; Tsukamoto, Masatoshi; Sasagawa, Takashi; Nishimura, Kazuya; Yamamoto, Ryuichi; Deguchi, Takashi; Takeyama, Kunihiko; Hosoki, Kanoo
CORPORATE SOURCE: Res. Lab., Dainippon Pharm. Co., Ltd., Suita, 564, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1989), 37(9), 2417-22
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:6781
GI For diagram(s), see printed CA Issue.
AB Title D-γ-glutamyl tripeptides, e.g. I (Z = PhCH2O2C; X = Lys, Phe, Ile, Trp, Ala, Pro), II (X = Lys, Orn, Arg, Phe, Ala), and III (X = Lys,

Orn, His, Phe, Gln, Pro, Gly, Glu, D-Phe), were prepared by solution methods. These tripeptides were tested as inhibitors of angiotensin-converting enzyme (ACE). The effect of varying the antepenultimate amino acid residue in this series on the biol. activity was studied. Introduction of Lys and Orn residues at the P1 position provided the most potent inhibitors, III (X = Lys, Orn), which exhibited an oral antihypertensive activity. This result suggests that basic amino acid residues at the P1 position play an important role in binding with the S1 subsite of ACE in this series. Oral antihypertensive activity of selected compds. was evaluated.

IT 127413-69-8P 127413-75-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and angiotensin converting enzyme-inhibiting activity of)

RN 127413-69-8 CAPLUS
CN L-Proline, 1-[N-[1-[(phenylmethoxy)carbonyl]-L-prolyl]-D-γ-glutamyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 127413-75-6 CAPLUS
CN D-Norvaline, 5-(2-carboxyoctahydro-1H-indol-1-yl)-5-oxo-N-[1-[(phenylmethoxy)carbonyl]-L-prolyl]-, [2S-(2α,3aβ,7aβ)]- (9CI) (CA INDEX NAME)



Erich Leeser

50613257

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1976:536369 CAPLUS
DOCUMENT NUMBER: 85:136369
TITLE: Stereochemistry of complexes of multidentate ligands. Part VI. Stereoselective cobalt(III) complexes of (3R)3-methyl-1,6-bis[(2S)-pyrrolidin-2-yl]-2,5-diazahexane and (3S)3-methyl-1,6-bis[(2S)-pyrrolidin-2-yl]-2,5-diazahexane
AUTHOR(S): Jun, Moo-Jin; Liu, Chui Fan
CORPORATE SOURCE: Dep. Chem., Univ. Illinois, Chicago, IL, USA
SOURCE: Journal of the Chemical Society, Dalton Transactions: Inorganic Chemistry (1972-1999) (1976), (12), 1031-6
CODEN: JCDTBI; ISSN: 0300-9246
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The optically active quadridentate ligands, I and II, were prepared from N-benzyloxycarbonyl-S-proline, iso-Bu chloroformate, and R- and S-propylenediamine, resp., followed by reduction, and their Co(III) complexes, cis- and trans-[CoCl2L]+, cis-[CoL(NO2)2]+, and cis-[CoL(C2O4)]+ (L = I, II) were synthesized. I and II coordinated stereospecifically in the cis geometry giving the Λ-cis-β and Δ-cis-β configurations, resp., and in the trans geometry giving optically active trans configurations. Uv, CD, and ORD spectra were determined to assign the absolute configurations of the complexes.

IT 60435-55-4P 60478-91-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 60435-55-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2,2'-[(1-methyl-1,2-ethanediyl)bis(iminocarbonyl)]bis-, bis(phenylmethyl) ester, stereoisomer (9CI) (CA INDEX NAME)



Erich Leeser

50613257

RN 60478-91-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2,2'-[(1-methyl-1,2-ethanediyl)bis(iminocarbonyl)]bis-, bis(phenylmethyl) ester, stereoisomer (9CI) (CA INDEX NAME)



=>
=> D HIS

(FILE 'HOME' ENTERED AT 13:25:14 ON 26 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:25:30 ON 26 MAR 2007
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 134 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:26:36 ON 26 MAR 2007
L4 7 S L3
L5 7 S L3 FULL
L6 5 S L5 AND PY<2003

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.82	209.58
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.90	-3.90

STN INTERNATIONAL LOGOFF AT 13:37:40 ON 26 MAR 2007

Erich Leeser